Deciphering the crosstalk among IL-1 and IL-10 family cytokines in intestinal immunity

Trends in Immunology

Volumn 36, Issue 8, 2015, Pages 471-478

  Manzanillo, Paolo ^a   Eidenschenk, Celine ^a   Ouyang, Wenjun ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 22; INTERLEUKIN 33;

COLON; CYTOKINE RESPONSE; ENTERITIS; IMMUNOPATHOGENESIS; INTESTINE; INTESTINE MUCOSA; MUCOSAL IMMUNITY; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TH17 CELL; ANIMAL; HUMAN; IMMUNOLOGY;

ANIMALS; HUMANS; INTERLEUKIN-1; INTERLEUKIN-10; INTESTINES;

EID: 84939571923     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2015.06.003     Document Type: Review

References (89)

1. Rescigno M. The intestinal epithelial barrier in the control of homeostasis and immunity. Trends Immunol. 2011, 32:256-264.
2. Turner J.R. Intestinal mucosal barrier function in health and disease. Nat. Rev. Immunol. 2009, 9:799-809.
3. Artis D. Epithelial-cell recognition of commensal bacteria and maintenance of immune homeostasis in the gut. Nat. Rev. Immunol. 2008, 8:411-420.
4. Hooper L.V., Macpherson A.J. Immune adaptations that maintain homeostasis with the intestinal microbiota. Nat. Rev. Immunol. 2010, 10:159-169.
5. Maynard C.L., et al. Reciprocal interactions of the intestinal microbiota and immune system. Nature 2012, 489:231-241.
6. Mowat A.M., Agace W.W. Regional specialization within the intestinal immune system. Nat. Rev. Immunol. 2014, 14:667-685.
7. Xavier R.J., Podolsky D.K. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007, 448:427-434.
8. Khor B., et al. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011, 474:307-317.
9. Van Limbergen J., et al. Advances in IBD genetics. Nat. Rev. Gastroenterol. Hepatol. 2014, 11:372-385.
10. Kanai T., et al. Clinical strategies for the blockade of IL-18 in inflammatory bowel diseases. Curr. Drug Targets 2013, 14:1392-1399.
11. Munoz M., et al. Interleukin (IL)-23 mediates Toxoplasma gondii-induced immunopathology in the gut via matrixmetalloproteinase-2 and IL-22 but independent of IL-17. J. Exp. Med. 2009, 206:3047-3059.
12. Sugimoto K., et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J. Clin. Invest. 2008, 118:534-544.
13. Arai Y., et al. Involvement of interleukin-1 in the development of ulcerative colitis induced by dextran sulfate sodium in mice. Cytokine 1998, 10:890-896.
14. Bersudsky M., et al. Non-redundant properties of IL-1α and IL-1β during acute colon inflammation in mice. Gut 2014, 63:598-609.
15. Garlanda C., et al. The interleukin-1 family: back to the future. Immunity 2013, 39:1003-1018.
16. Ouyang W., et al. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu. Rev. Immunol. 2011, 29:71-109.
17. Sims J.E., Smith D.E. The IL-1 family: regulators of immunity. Nat. Rev. Immunol. 2010, 10:89-102.
18. Chen C.J., et al. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat. Med. 2007, 13:851-856.
19. Eigenbrod T., et al. Cutting edge: critical role for mesothelial cells in necrosis-induced inflammation through the recognition of IL-1 alpha released from dying cells. J. Immunol. 2008, 181:8194-8198.
20. Moussion C., et al. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'?. PLoS ONE 2008, 3:e3331.
21. Verri W.A., et al. IL-33 induces neutrophil migration in rheumatoid arthritis and is a target of anti-TNF therapy. Ann. Rheum. Dis. 2010, 69:1697-1703.
22. Casini-Raggi V., et al. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. J. Immunol. 1995, 154:2434-2440.
23. Pastorelli L., et al. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:8017-8022.
24. Pizarro T.T., et al. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells. J. Immunol. 1999, 162:6829-6835.
25. Kojouharoff G., et al. Neutralization of tumour necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice. Clin. Exp. Immunol. 1997, 107:353-358.
26. Kanai T., et al. Macrophage-derived IL-18-mediated intestinal inflammation in the murine model of Crohn's disease. Gastroenterology 2001, 121:875-888.
27. Siegmund B., et al. Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-γ and TNF-α production. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2001, 281:R1264-R1273.
28. Takagi H., et al. Contrasting action of IL-12 and IL-18 in the development of dextran sodium sulphate colitis in mice. Scand. J. Gastroenterol. 2003, 38:837-844.
29. Fiorentino D.F., et al. IL-10 inhibits cytokine production by activated macrophages. J. Immunol. 1991, 147:3815-3822.
30. de Waal Malefyt R., et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J. Exp. Med. 1991, 174:915-924.
31. Rubtsov Y.P., et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity 2008, 28:546-558.
32. Glocker E.O., et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N. Engl. J. Med. 2009, 361:2033-2045.
33. Kuhn R., et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993, 75:263-274.
34. Sellon R.K., et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect. Immun. 1998, 66:5224-5231.
35. Eyerich S., et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J. Clin. Invest. 2009, 119:3573-3585.
36. Liang S.C., et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J. Exp. Med. 2006, 203:2271-2279.
37. H17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007, 445:648-651.
38. Cella M., et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature 2009, 457:722-725.
39. + cell populations in gut and skin. Nat. Immunol. 2009, 10:75-82.
40. + cells. Nat. Immunol. 2009, 10:83-91.
41. + cells that provide innate mucosal immune defense. Immunity 2008, 29:958-970.
42. Rutz S., et al. The IL-20 subfamily of cytokines - from host defence to tissue homeostasis. Nat. Rev. Immunol. 2014, 14:783-795.
43. Zenewicz L.A., et al. Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity 2008, 29:947-957.
44. Zheng Y., et al. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat. Med. 2008, 14:282-289.
45. lo) CD4 T cells are controlled directly by IL-10 and cause IL-22-dependent intestinal pathology. J. Exp. Med. 2011, 208:1027-1040.
46. + mononuclear phagocytes support colitis-associated innate lymphoid cell production of IL-22. J. Exp. Med. 2014, 211:1571-1583.
47. Munoz M., et al. Interleukin-22 induces interleukin-18 expression from epithelial cells during intestinal infection. Immunity 2015, 42:321-331.
48. + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 2005, 6:1123-1132.
49. Korn T., et al. IL-17 and Th17 Cells. Annu. Rev. Immunol. 2009, 27:485-517.
50. Park H., et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 2005, 6:1133-1141.
51. Duhen T., et al. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat. Immunol. 2009, 10:857-863.
52. H17 cells. Nat. Immunol. 2011, 12:1238-1245.
53. H2 cells. Nat. Immunol. 2009, 10:864-871.
54. Basu R., et al. Th22 cells are an important source of IL-22 for host protection against enteropathogenic bacteria. Immunity 2012, 37:1061-1075.
55. Veldhoen M., et al. TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006, 24:179-189.
56. Langrish C.L., et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 2005, 201:233-240.
57. H-17 cell-mediated pathology. Nat. Immunol. 2007, 8:1390-1397.
58. H17 cells in the absence of TGF-β signalling. Nature 2010, 467:967-971.
59. Chung Y., et al. Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity 2009, 30:576-587.
60. Hu W., et al. Priming microenvironments dictate cytokine requirements for T helper 17 cell lineage commitment. Immunity 2011, 35:1010-1022.
61. Sutton C., et al. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J. Exp. Med. 2006, 203:1685-1691.
62. Acosta-Rodriguez E.V., et al. Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17-producing human T helper cells. Nat. Immunol. 2007, 8:942-949.
63. + Th1/17 cells that are specific for pathogenic and commensal microbes. J. Immunol. 2014, 193:120-129.
64. Mathur A.N., et al. Stat3 and Stat4 direct development of IL-17-secreting Th cells. J. Immunol. 2007, 178:4901-4907.
65. McNamee E.N., et al. Interleukin 37 expression protects mice from colitis. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:16711-16716.
66. Jiang H.R., et al. IL-33 attenuates EAE by suppressing IL-17 and IFN-γ production and inducing alternatively activated macrophages. Eur. J. Immunol. 2012, 42:1804-1814.
67. Spits H., Di Santo J.P. The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling. Nat. Immunol. 2011, 12:21-27.
68. Mortha A., et al. Microbiota-dependent crosstalk between macrophages and ILC3 promotes intestinal homeostasis. Science 2014, 343:1249288.
69. Ahn Y.O., et al. Human group 3 innate lymphoid cells express DR3 and respond to TL1A with enhanced IL-22 production and IL-2-dependent proliferation. Eur. J. Immunol. 2015, Published online June 5, 2015. 10.1002/eji.201445213.
70. - lymphoid cells. EMBO J. 2011, 30:2934-2947.
71. Kolinska J., et al. Constitutive expression of IL-18 and IL-18R in differentiated IEC-6 cells: effect of TNF-α and IFN-γ treatment. J. Interferon Cytokine Res. 2008, 28:287-296.
72. Munoz M., et al. Immunology of Toxoplasma gondii. Immunol. Rev. 2011, 240:269-285.
73. Huber S., et al. IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature 2012, 491:259-263.
74. Martin J.C., et al. Interleukin-22 binding protein (IL-22BP) is constitutively expressed by a subset of conventional dendritic cells and is strongly induced by retinoic acid. Mucosal Immunol. 2014, 7:101-113.
75. Zhang B., et al. Viral infection. Prevention and cure of rotavirus infection via TLR5/NLRC4-mediated production of IL-22 and IL-18. Science 2014, 346:861-865.
76. Hernandez P.P., et al. Interferon-λ and interleukin 22 act synergistically for the induction of interferon-stimulated genes and control of rotavirus infection. Nat. Immunol. 2015, 16:698-707.
77. Hoshi N., et al. MyD88 signalling in colonic mononuclear phagocytes drives colitis in IL-10-deficient mice. Nat. Commun. 2012, 3:1120.
78. Sakaguchi S., et al. Regulatory T cells and immune tolerance. Cell 2008, 133:775-787.
79. Smith P.M., et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 2013, 341:569-573.
80. Atarashi K., et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature 2013, 500:232-236.
81. Furusawa Y., et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 2013, 504:446-450.
82. Arpaia N., et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 2013, 504:451-455.
83. + regulatory T cells allows for their purification from expansion cultures. Blood 2009, 113:5125-5133.
84. Bettelli E., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
85. Gagliani N., et al. Th17 cells transdifferentiate into regulatory T cells during resolution of inflammation. Nature 2015, Published online April 29, 2015. 10.1038/nature14452.
86. Basu R., et al. IL-1 signaling modulates activation of STAT transcription factors to antagonize retinoic acid signaling and control the TH17 cell-iTreg cell balance. Nat. Immunol. 2015, 16:286-295.
87. Schiering C., et al. The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature 2014, 513:564-568.
88. Shouval D.S., et al. Interleukin-10 receptor signaling in innate immune cells regulates mucosal immune tolerance and anti-inflammatory macrophage function. Immunity 2014, 40:706-719.
89. Zigmond E., et al. Macrophage-restricted interleukin-10 receptor deficiency, but not IL-10 deficiency, causes severe spontaneous colitis. Immunity 2014, 40:720-733.